

SRI Shenandoah Valley Center for Advanced Drug Research (SRI SV CADRE)

SRI Shenandoah Valley was established in December 2006 in Harrisonburg, Virginia; CADRE developed as part of the Biosciences Division of SRI International, which carries out basic research, drug discovery, and drug development and provides contract services. CADRE's mission is to find new ways to prevent, detect, and treat diseases of global importance by applying proteomics and protein engineering technologies. Research that supports this mission falls into three main areas: biotechnology, pharmaceuticals, and biosciences research. The Center currently employs about 40 staff members; with increased research opportunities and funding CADRE hopes to increase the number to 45 by the end of 2011. A leader in providing education and training to the academic community CADRE's workforce is a fusion of experienced research leaders, post-doctoral fellows in training, and undergraduate interns drawn from Virginia institutions.

Research at SRI SV CADRE is applied to three primary health issues:

- Global health and infectious diseases, including finding new diagnostics and therapies for tuberculosis and mosquito-borne illnesses (malaria and chikungunya) and addressing biothreat agents
- Metabolic diseases, focusing on diabetes, particularly diabetes related to insulin-resistance, as well as on drugs and biomarkers capable of more accurately predicting diabetes
- Biomarker discovery, leading to new diagnostics and therapies, as well as providing the foundation to personalized medicine

CADRE's research focus and strategic direction are regularly evaluated in light of industry advances and external funding trends. Every five years, a long-term vision is developed, identifying areas where CADRE can position itself as a leader in cutting-edge research.